Market news

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]

The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.

TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.

Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutic

BioXcel Therapeutics (BTAI) has entered into an agreement with Teva Pharmaceutical Industries (TEVA)

Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +3.92% and -46.47%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?